Associated Papers
Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States.
George SL et al.
Cancer Discovery, 2025
39693475 (PubMed )
Supplement: cd-24-0916_supplementary_table_2_suppst2.xlsx › Sheet1
Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.
Ek T et al.
Cancer Research Communications, 2024
39177282 (PubMed )
Supplement: crc-24-0338_supplementary_information_suppsi.docx
Benefits for children with suspected cancer from routine whole-genome sequencing.
Hodder A et al.
Nature Medicine, 2024
Genomic ALK alterations in primary and relapsed neuroblastoma.
Rosswog C et al.
British Journal of Cancer, 2023
36807339 (PubMed )
Supplement: 41416_2023_2208_MOESM1_ESM.pdf
Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing.
Szymansky A et al.
Journal of Personalized Medicine, 2021
34442335 (PubMed )
Supplement: jpm-11-00691-s001.zip › S15-SNVs_routine_cohort.xlsx › SNVs_Bigcohort
Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation.
Patil K et al.
Proceedings of the National Academy of Sciences of the United States of America, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
34630336 (PubMed )
Supplement: Table_1.xlsx › Tab2
Computational algorithms for in silico profiling of activating mutations in cancer.
Jordan EJ et al.
Cellular and Molecular Life Sciences : Cmls, 2019
Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Lambertz I et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Bresler SC et al.
Cancer Cell, 2014
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
Schulte JH et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
Passoni L et al.
Cancer Research, 2009
Select a paper to view details